Why the FDA backs ASX-biotech to revolutionise cancer treatment
One in five people will get cancer in their lifetime – almost everyone has been...
One in five people will get cancer in their lifetime – almost everyone has been...
Pitt Street Research has released an equity valuation report on clinical stage oncology company Prescient...
Prescient Therapeutics (ASX: PTX) reported encouraging results in several key targeted and cell therapies in...
Prescient Therapeutics (ASX: PTX) has been invited to present clinical data at the prestigious American...
Prescient Therapeutics (ASX: PTX) had a solid FY23 that has set the stage for a...
Clinical stage oncology company Prescient Therapeutics Ltd (ASX: PTX) has finished off another strong quarter...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) presented exciting new data on their OmniCAR...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed highly experienced US biotech executive...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has just presented at the Cell &...
Clinical stage oncology company, Prescient Therapeutics (ASX: PTX), has received an expanded Orphan Drug Designation...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.